Company: MBIO
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001410578-25-000028
Chunk: 17

Company: MUSTANG BIO, INC.
Filing Date: 2025-01-15
Form: S-1
Chunk 17
---
 be available on commercially reasonable terms. |

Risks Relating to Legislation and Regulation Affecting the Biopharmaceutical and Other Industries

| ● | We operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations, particularly with the new presidential administration in the United States. |

| ● | We may be subject to anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings. |

| ● | We are subject to numerous environmental, health and safety laws and regulations and could become subject to fines or penalties or incur costs that could harm our business. |

Risks Pertaining to Intellectual Property and Potential Disputes with Licensors Thereof

| ● | If we are unable to obtain and maintain sufficient patent protection for our technology and products, our competitors could develop and commercialize products similar or identical to ours and our ability to successfully commercialize our technology and products could therefore be impaired. |

| ● | We depend on our licensors to maintain and enforce the intellectual property rights covering certain of our product candidates. |

| ● | We or our licensors may be subject to costly and time-consuming litigation for infringement of third-party intellectual property rights or to enforce our or our licensors’ intellectual property rights against third-party infringers. |

| ● | Any dispute with our licensors may affect our ability to develop or commercialize our product candidates. |

Risks Relating to Our Control by Fortress Biotech, Inc. (“Fortress”)

| ● | Fortress controls a voting majority of our common stock and has the right to receive significant share grants annually, which will result in dilution of our other stockholders and could reduce the value of our common stock. |

| ● | We have entered into certain agreements with Fortress and may have received better terms from unaffiliated third parties. |

| ● | We share certain directors with Fortress, which could create conflicts of interest between us and Fortress. |

Risks Relating to this Offering

| ● | You will experience immediate dilution in the book value per share of the common stock purchased in the offering. |

| ● | If you purchase our securities in this offering, you may experience future dilution as a result of future equity offerings or other equity issuances. |

| ● | A substantial number of shares of common stock